Prevention of mammary carcinogenesis in MMTV‐neu mice by targeting RLIP. Issue 3 (5th February 2021)

• Record Type: Journal Article
• Authors: Singhal, Jyotsana; Kulkarni, Prakash; Horne, David; Awasthi, Sanjay; Salgia, Ravi; Singhal, Sharad S.
• Is Part Of: Molecular carcinogenesis. Volume 60:Issue 3(2021)
• Page Start: 213
• Page End: 223
• Publication Date: 2021-02-05
• Subjects: breast cancer -- MMTV‐neu mice -- prevention -- RalBP1 -- RLIP; Carcinogenesis -- Molecular aspects -- Periodicals; 616.994071
• DOI: 10.1002/mc.23285
• Languages: English
• ISSNs: 0899-1987

Abstract

Abstract: The overexpression and amplification of the protooncogene neu (ERBB2) play an important role in the development of aggressive breast cancer (BC) in humans. Ral‐interacting protein (RLIP), a modular stress‐response protein with pleiotropic functions, is overexpressed in several types of cancer, including BC. Here, we show that blocking RLIP attenuates the deleterious effects caused by the loss of the tumor suppressor p53 and inhibits the growth of human BC both in vitro and in vivo in MMTV‐ neu mice. In addition, we show that treatment with the diet‐derived, RLIP‐targeting chemotherapeutic 2′‐hydroxyflavanone (2HF), alone or in combination with RLIP‐specific antisense RNA or antibodies, significantly reduced the cumulative incidence and/or burden of mammary hyperplasia and carcinoma in MMTV‐ neu mice. 2HF treatment correlated with reduced tumor cell proliferation and increased apoptosis, and the average number of Ki67‐positive (proliferating) cells was significantly lower in the tumors of 2HF‐treated mice than in the tumors of control mice. Furthermore, targeting RLIP also resulted in the overexpression of E‐cadherin and the infiltration of CD3 + T cells into mammary tumors. Taken together, these results underscore the translational potential of RLIP‐targeting agents and provide a strong rationale to validate them in the clinic.